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Obesity is a risk factor for postmenopausal breast cancer. Adiponectin/Acrp30 is lower in obese individuals and may be negatively
regulating breast cancer growth. Here we determined that five breast cancer cell lines, MDA-MB-231, MDA-MB-361, MCF-7, T47D,
and SK-BR-3, expressed one or both of the Acrp30 receptors. In addition, we found that the addition of Acrp30 to MCF-7,
T47D, and SK-BR-3 cell lines inhibited growth. Oestrogen receptor (ER) positive MCF-7 and T47D cells were inhibited at lower
Acrp30 concentrations than ER-negative SK-BR-3 cells. Growth inhibition may be related to apoptosis since PARP cleavage was
increased by Acrp30 in the ER-positive cell lines. To investigate the role of ER in the response of breast cancer cells to Acrp30, we
established the MDA-ERa7 cell line by insertion of ER-a into ER-a-negative MDA-MB-231 cells. This line readily formed tumours in
athymic mice and was responsive to oestradiol in vivo. In vitro, MDA-ERa7 cells were growth inhibited by globular Acrp30 while the
parental cells were not. This inhibition appeared to be due to blockage of JNK2 signalling. These results provide information on how
obesity may influence breast cancer cell proliferation and establish a new model to examine interactions between ER and Acrp30.
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Obesity plays an important role in several aspects of postmeno-
pausal breast cancer. For example, obesity is associated with
increased risk for postmenopausal breast cancer (Trentham-Dietz
et al, 2000; Morimoto et al, 2002; Carmichael, 2006). In addition,
there are clinical studies indicating that increased BMI is
associated with more aggressive breast cancer and a reduced
survival period (Cleary and Maihle, 1997; Sweeney et al, 2004;
Loi et al, 2005; Porter et al, 2006). Obesity may mediate its effects
on breast cancer due to the fact that adipose tissue secretes a
number of different factors that are commonly referred to as
‘adipokines’ (Vona-Davis and Rose, 2007). One adipokine
potentially involved in the interaction between breast cancer and
obesity is adiponectin, also known as adipocyte complement-
related protein of 30kDa (Acrp30) (Scherer et al, 1995). In contrast
to most adipose-secreted proteins, Acrp30 is negatively correlated
with body weight, body mass index, body fat, and serum leptin in
women independent of age (Ryan et al, 2003). It has also been
shown to be negatively regulated by 17b-oestradiol in vitro (Kim
et al, 2005); and in vivo,( I met al, 2006; Laughlin et al, 2007)
although some studies do not find such regulation (Sieminska
et al, 2005; Kleiblova et al, 2006).
Acrp30 was previously implicated in a number of pathological
conditions. For example, decreased plasma Acrp30 levels are
associated with certain insulin resistant states such as type 2
diabetes and coronary artery disease (Kadowaki and Yamauchi,
2005). Furthermore, specific factors associated with protection for
some disease states such as decreased levels of triglycerides,
increased insulin sensitivity, and increased high-density lipopro-
tein cholesterol levels are associated with increasing levels of
plasma Acrp30 (Yamauchi et al, 2003b; Oh et al, 2007)
Additionally general anti-inflammatory and anti-vascular effects
are associated with high Acrp30 levels (Hopkins et al, 2007; Ouchi
and Walsh, 2007). As has previously been shown for other
adipokines, Acrp30 appears to have global effects on a number of
different aspects of physiology and cell growth.
Acrp30 is found at high concentrations (2–20mgml
 1) in human
serum (Arita et al, 1999; Bondanelli et al, 2001; Miyoshi et al, 2003;
Mantzoros et al, 2004; Chen et al, 2006; Korner et al, 2007; Takahata
et al, 2007). There are several different forms of Acrp30 in plasma
that bind with varying affinity to the two different Acrp30
receptors, AdipoR1, and AdipoR2 (Yamauchi et al, 2003a). Full-
length Acrp30 exists either as a trimer known as the low molecular
weight form or as two larger multimers classified as middle
molecular weight and high molecular weight forms (Tsao et al,
2002). Full-length Acrp30 binds with highest affinity to AdipoR2,
which is most abundant in liver (Yamauchi et al, 2003a). Acrp30
can also be cleaved and exist in serum as a trimer of the smaller
molecules known as globular Acrp30 (gAcrp30) (Fruebis et al,
2001). The gAcrp30 binds with highest affinity to AdipoR1, which
has previously been shown to be expressed by a number of tissues
including, brain, heart, kidney, liver, lung, spleen, and skeletal
muscle (Yamauchi et al, 2003a). A problem that has arisen is that
most publications do not specify the form(s) of Acrp30 that they
are investigating. Thus, the functions of the different forms of
Acrp30 and which form(s) are of the most importance in
pathophysiological functions are still under active investigation.
With respect to breast cancer, lower serum Acrp30 levels have
been reported for postmenopausal women with breast cancer
(Bondanelli et al, 2001; Miyoshi et al, 2003; Mantzoros et al, 2004).
In vitro assays have indicated that the addition of Acrp30 to the
human MDA-MB-231 breast cancer cell line-induced growth arrest
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sand promoted apoptosis (Kang et al, 2005; Wang et al, 2006).
Addition of Acrp30 also blocked phosphorylation of Akt and
reduced the expression of cyclin D1 (Wang et al, 2006). It has also
been reported that under some conditions the normal response of
T47D human breast cancer cells to the growth factors in serum can
be blocked by Acrp30. In addition, Acrp30 was reported to have
some effect on growth inhibition of two other cell lines, Hs578T
and SK-BR-3, but no effect on the growth of MCF-7 and HCC-38
cells (Kang et al, 2005). However, other publications found that
growth of MCF-7 cells was negatively regulated by Acrp30
(Dieudonne et al, 2006; Arditi et al, 2007) and one of these studies
indicated that apoptosis was induced (Dieudonne et al, 2006).
Acrp30 inhibited angiogenesis using in vitro and in vivo assays
of non-breast cancer cell lines and the intratumoral injection
of Acrp30 suppressed T241 fibrosarcoma tumour growth
(Brakenhielm et al, 2004).
When discussing obesity and postmenopausal breast cancer
it is important to consider that adipose tissue is the major
source of oestrogen. Oestrogen is an important biological factor
promoting breast cancer development in oestrogen receptor
(ER) positive tumours (Hemsell et al, 1974). The effects of
estrogens are mediated by oestrogen receptor a (ERa) and
oestrogen receptor b (Speirs and Walker, 2007) and it is possible
for the receptors to function in the absence of ligand under certain
conditions (Speirs and Walker, 2007). In general, ERa is felt to be
responsible for cell growth while ERb may block cell growth. Since
many tissues express both genes it is likely that the ratio of the two
receptors is responsible for the overall effects of oestrogen on a
given tissue.
Here we have investigated the effects of Acrp30 and ERa in the
absence of other factors such as oestradiol, leptin or serum on a
number of breast cancer cell lines to clarify the role of Acrp30 on
cell growth and how ERa without significant doses of high-affinity
ligands may affect this role. In addition, we have generated new
cell lines by inserting the ERa gene into the oestrogen
unresponsive MDA-MB-231 breast cancer cell line (Cailleau et al,
1978) which are designated MDA-ERa5 and MDA-ERa7. We then
used these lines to further investigate the potential interactions of
ERa and different forms of Acrp30 on cell growth both in vitro and
in vivo. Finally, we identified alterations in signalling pathways
utilised by the ERa-negative and ERa-positive breast cancer cells in
response to Acrp30 and the naturally occurring, truncated form
known as gAcrp30.
MATERIALS AND METHODS
Cell culture
MCF-7, T47D, MDA-MB-361, SK-BR-3, and MDA-MB-231 cells
were obtained from ATCC (Manassas, VA, USA) and maintained
in L-15 media (ATCC, Manassas, VA, USA) with 10% fetal calf
serum (FCS) (Atlanta Biologics, Lawrenceville, GA, USA) and pen/
strep (Gibco, Grand Island, NY, USA). Clones of the MDA-MB-231
cell line that had been transfected with the ERa gene were obtained
by selection with 200mgml
 1 of zeocin (Promega, Madison, WI,
USA) and clonal lines were maintained in 200mgml
 1 zeocin
containing media.
Growth assays and cell signalling
For the assays shown in Figure 1 on the MCF-7, T47D, MDA-MB-
361, SK-BR-3, and MDA-MB-231, cells were harvested and counted
using a coulter counter, plated at a density of 5 10
3 cells per well
in 96-well plates, and allowed to attach overnight in an incubator.
The following day, complete medium was removed from the wells,
replaced with serum-free medium, and the cells returned to the
incubator for 18–24h (to allow for cell cycle synchronisation).
Treatment with Acrp30 was then performed and the cells
incubated for 48h, at which time a cell proliferation assay was
performed. For growth assays shown in Figure 4 comparing the
MDA-wt and MDA-ERa7 cells 5 10
3 cells per well were placed in
96-well plates. The following morning the media was replaced with
serum-free L-15 with or without other factors as described in the
figure legend. For the experiments in Figures 2 and 5, cells were
plated at 5 10
5 in 6-well plates. The following day the media
was replaced with various amounts of Acrp30 (RND
Systems, Minneapolis, MN, USA) or gAcrp30 (Cell Sciences,
Canton, MA, USA) or as described for each experiment. After 24h
of treatment the cells were either harvested or treated for various
times with FCS. The growth assay was performed using 10mlo f
CCK-8 reagent from the Cell Counting Kit-8 as per manufacturer’s
instructions (Dojindo Laboratories, Japan). In this assay a
formazan dye is generated by the activity of dehydrogenases in
cells that is directly proportional to the number of living cells. The
plates were then incubated for 1.5 to 3h depending on the cell line
in a CO2 incubator, after which the plates were read on an ELISA
reader at 450nm. A standard curve was included on each plate to
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Figure 1 Growth curves for breast cancer cell lines in response to increasing concentrations of Acrp30. (A) MCF-7, (B) T47-D, (C) MDA-MB-361, (D)
SK-BR-3 and (E) MDA-MB-231 cells. The concentration of Acrp30 in ngml
 1 is shown below each graph. Each point represents three or more wells.
*Indicates significantly different from 0ngml
 1 as defined by ANOVA p¼0.0002, Dunnett’s multiple comparison post-test Po0.01.
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sallow for estimation of approximate cell numbers in the treated
wells, as was appropriate with negative and/or positive controls.
Western blots
All whole cell extracts were obtained as per the manufacturer’s
instructions for Novagen Phosphosafe extraction reagent (Merck
KGaA, Darmstadt, Germany) and the amount of protein quanti-
tated and standardised. Western analyses were performed with
antibodies from Santa Cruz Biotechnology (Santa Cruz, CA, USA)
except antibodies to AdipoR1 were obtained from Chemicon
(Millipore, Billerica, MA, USA), AdipoR2 from Phoenix Pharma-
ceuticals Inc., (Burlingame, CA, USA), and anti-rabbit secondary
from Cell Signalling Inc., (Danvers, MA, USA). Approximately
20mg of protein were run in each lane. The protein was transferred
to PVDF membrane and checked for uniformity using Poceau S
and then blocked with PBST with 5% milk. Primary antibodies
were incubated in PBST with 5% milk overnight. Blots were then
washed and incubated with appropriate AP-linked secondary
antibodies, washed again and incubated with ECF substrate for
30min. Blots were then visualised with a STORM 840 (Molecular
Dynamics, Sunnyvale, CA, USA). Results were quantitated using
UN-SCAN-IT software and normalised to b-actin.
Animal experiments
Rag1 athymic C57BL6 female mice were obtained from Jackson
Laboratories (Bar Harbor, ME, USA) at 5–6 weeks of age. This
mouse strain was chosen because our long-term goal is to evaluate
effects of dietary obesity using these cell lines and we recently
reported that these mice readily develop dietary obesity when fed a
purified high-fat diet (Ray et al, 2007). The implantation protocol
was similar to the one we published previously (Ray et al, 2007). In
brief, mice were housed three per cage and water was provided on
an ad libitum basis. All mice were fed a purified diet based on AIN-
93M (Harlan Teklad, Madison, WI, USA) recommendations for
long-term maintenance of rodents. Mice in experiment 1 (exp 1)
were intact but those in experiment 2 (exp 2) were ovariectomised.
At 7 (exp 1) or 10 (exp 2) weeks of age mice were implanted with
120-day 17b-oestradiol pellets or control pellets (Innovative
Research of America, Sarasota, FL, USA). They were then injected
on the flank (exp 1) or in the mammary fat pad (exp 2) with either
3 10
6 MDA-MB-231, MDA-ERa5 (exp 1 only) or MDA-ERa7 cells
mixed 1:1 with matrigel (BD Biosciences, Bedford, MA, USA).
Mice were weighed and palpated for tumours weekly for 10 weeks.
At the termination of the experiment, the mice were euthanised
and tumours removed, measured, and weighed. The Hormel
Institute Animal Facility is AAALAC accredited. The University of
Minnesota Animal Care and Use Committee approved this study.
RESULTS
Effects of Acrp30 on ER-positive and ER-negative human
breast cancer cell lines in vitro
The cell lines; MCF-7 (ERþ), T47D (ERþ), MDA-MB-361
(ERþ), SK-BR-3 (ER-), and MDA-MB-231 (ER-) were used for
our initial experiments. We determined quantitatively how Acrp30
affects cell proliferation. Experiments were conducted in serum-
free media to identify alterations due to direct Acrp30 signalling.
Figure 1 illustrates that in the absence of serum even low levels of
full-length Acrp30 are able to cause a reduction in cell proliferation
of the ERaþ cell lines, MCF-7, and T47D (50ngml
 1 or more and
200ngml
 1 or more respectively). At somewhat higher concentra-
tions (500ngml
 1 or more) of Acrp30, there was also a significant
reduction in growth of the ERa-negative SK-BR-3 cells. There was
no significant reduction in the proliferative growth of MDA-MB-
361 and MDA-MB-231 cell lines at these concentrations of Acrp30.
In conjunction with the cell proliferation assays, western blot
analyses of a number of proteins involved in cell proliferation,
apoptosis, inflammation, and vascularisation were performed to
determine how their levels changed in response to Acrp30
treatment. The breast cancer cells were treated with 1mgml
 1 of
Acrp30 for 24h prior to cell harvest. Figure 2A highlights some of
these findings showing that AdipoR2 was detected in all five cell
lines. However, MDA-MB-361 cells did not have detectable
AdipoR1 while the other four cell lines did. The level of AdipoR2
was upregulated in MCF-7 cells, but slightly downregulated in
MDA-MB-361 and MDA-MB-231 cells 24h after addition of
1mgml
 1 of Acrp30. The long form of the leptin receptor, Ob-Rb
was detected in all of the cell lines and expression increased in the
MCF-7 and T47D cells in response to addition of Acrp30.
We measured two different proteins, which are indicators of cell
growth, PCNA, and cyclin D1. We found little effect of addition of
Acrp30 on either protein although it appeared that PCNA levels
tended to be reduced while the cyclin D1 levels tended to increase.
We also examined the opposite side of growth, death. Increased
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Figure 2 Western analysis of protein regulation by Acrp30. (A) The
individual cell lines are shown above their two corresponding lanes on the
gels. Minus symbols above the lanes indicate extracts from untreated cells
and plus symbols above the lanes indicate extracts from cells treated with
1mgml
 1 Acrp30 for 24h. The proteins detected are shown to the left of
the figure. Abbreviations are AdipoR1¼adiponectin receptor 1; Adi-
poR2¼adiponectin receptor 2; Ob-Rb¼leptin receptor isoform b;
PCNA¼proliferating cell nuclear antigen and PARP¼Poly (ADP-ribose)
polymerase. (B) Densitometry of cleaved caspase 8 (solid bars) and
cleaved PARP (checkered bars) normalised to b-actin. The x axis shows the
different cell lines tested without Acrp30 ( ) or with Acrp30 (þ). The y
axis is percent where 100% is the value of each cell line without Acrp30.
Note: cleaved PARP was not detected in SK-BR-3 and MDA-MB-231 cells
under these conditions.
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slevels of cleaved caspase 8 were detected in the ERþ cell lines,
MCF-7, and MDA-MB-361 but little or no increase was seen in the
other cell lines in response to the addition of Acrp30. Increased
PARP cleavage was detected in all of the ERþ cell lines but not in
the ER  cell lines. Figure 2B shows densitometry results of the
blots presented in Figure 2A for cleaved caspase 8 and cleaved
PARP normalised to b-actin.
Tables 1–4 provide an overview of all of the different proteins
tested. In addition to the results described above Table 1 shows
that Acrp30 was able to regulate the receptors for the growth
factors, leptin (Ob-Rb), progesterone (PRa and PRb), epidermal
growth factor and androgen, in a manner that was cell type
specific. However, IGFIRa was not regulated by Acrp30 in any of
the cell lines tested. Both leptin and Acrp30 were also detected in
all of the cell lines and were regulated in a cell line specific manner.
In Table 2 we found that Acrp30 affected signalling through p-p38,
p-JNK p-Akt (Thr308), and p-Akt (Ser473) in a cell line specific
manner after 24h of treatment. Jak2, Stat3, and PKCa were also
regulated in a cell line specific manner. Table 3 shows a number of
different proteins related to apoptosis. We found that while
caspase-8 and PARP were regulated by Acrp30 (Figure 2) there was
very little regulation of Bcl-2, Bcl-XL, Mcl-1L, Mcl-1S, Bax, and Bak
although Mcl-1S was increased in MDA-MB-231 cells and
Bax was increased in MCF-7 cells. In addition, the levels of
cleaved caspase-3, caspase-6, and caspase-9 did not change in
response to Acrp30 in any of the cell lines. Table 4 shows a number
of proteins involved in tumour proliferation and adhesion. We
found that many of these proteins were altered by Acrp30. For
example, Cox-2 expression was increased in the MCF-7 and T47D
cells but not in the other lines when the cells were treated with
Acrp30. Expression of VEGF was increased in the T47D and SK-
BR-3 cells and decreased in the MDA-MB-361 cells when Acrp30
was added. Laminb-3 was increased in MCF-7 cells and E-cadherin
was increased in T47D cells but decreased in MDA-MB-361 cells.
All of this suggests that Acrp30 has profound effects on many
different genes involved in tumour proliferation and adhesion but
in a cell type specific manner.
Addition of ER-a to MDA-MB-231 ER-negative human
breast cancer cells
Our results in Figure 1 suggest that the ER status of the
breast cancer cells may cause them to be more sensitive to
the growth inhibition of Acrp30. To better examine the role of ERa
on the Acrp30 effects we added ERa into the oestrogen
unresponsive cell line MDA-MB-231 (MDA-wt) using liposome-
Table 1 Acrp30 regulation of potential growth factors and their
receptors
MCF-7 T47D MDA-MB-231 MDA-MB-361 SK-BR-3
AdipoR1      ud  
AdipoR2 + n/c    n/c
Ob-Rb + +   n/c n/c
PRa +   ud ud ud
PRb ud + ud ud ud
EGFR ud n/c   ud  
p-EGFR ud ud   ud n/c
LXRa n/c n/c n/c n/c n/c
LXRb + + n/c n/c n/c
AR n/c + ud   ud
IGFIRa n/c n/c n/c n/c n/c
Leptin + + n/c n/c n/c
Acrp30   + + n/c +
 ¼decrease; n/c¼no change; +¼increase; AdipoR¼adiponectin receptor;
AR¼androgen receptor; EGFR¼epidermal growth factor receptor;
IGFIR¼insulin-like growth factor-I receptor; LXR¼liver x receptor; Ob-R¼leptin
receptor; p¼phosphorylated; PR¼progesterone receptor; ud¼undetected.
Table 2 Acrp30 alteration of potential signalling proteins.
MCF-7 T47D MDA-MB-231 MDA-MB-361 SK-BR-3
Jak2 + +    n/c
Stat3 n/c + + n/c  
PI3K n/c n/c n/c n/c n/c
p-p38   n/c n/c n/c n/c
p-JNK1/2 + n/c n/c n/c  
p-Akt308   + n/c n/c n/c
p-Akt473 n/c + n/c n/c n/c
PKCa + + n/c   n/c
 ¼decrease; n/c¼no change; +¼increase; Jak¼janus kinase; JNK¼c-jun amino-
terminal kinase; PI3K¼phosphatidylinositol 3-kinase; PKC¼protein kinase C¼Stat:
signal transducer and activator of transcription; ud¼undetected.
Table 3 Effects of Acrp30 on proteins involved in apoptosis
MCF-7 T47D MDA-MB-231 MDA-MB-361 SK-BR-3
Bcl-2 n/c ud n/c n/c n/c
Bcl-XL n/c n/c n/c n/c n/c
Mcl-1L n/c n/c n/c n/c n/c
Mcl-1S n/c n/c n/c n/c +
Bax + n/c n/c ud n/c
Bak n/c n/c n/c n/c n/c
FL-Caspase-3 ud   +   +
Cleaved Caspase-3 ud n/c n/c n/c n/c
FL-Caspase-6 +   n/c ud  
Cleaved Caspase-6 ud ud ud ud ud
FL-Caspase-8 +    n/c +
Cleaved Caspase-8 + n/c   +n / c
Caspase-9 +   n/c n/c n/c
Cleaved Caspase-9 ud ud ud ud ud
FL-PARP n/c + ud ud ud
Cleaved PARP + + ud + ud
 ¼decrease; n/c¼no change; +¼increase; Cl¼cleaved; Fl¼full length;
PARP¼poly-ADP-ribose polymerase; ud¼undetected.
Table 4 Effects of Acrp30 on proteins involved in tumor proliferation
and adhesion
MCF-7 T47D MDA-MB-231 MDA-MB-361 SK-BR-3
TP53 + + n/c ud n/c
p-TP53(Ser 315) N/c n/c n/c   n/c
p-TP53(Ser392) + n/c   n/c  
p-TP53(hSer20) n/c + n/c ud +
SHBG + n/c n/c   
IGFBP3 + n/c n/c n/c n/c
Mdr n/c n/c n/c n/c ud
PCNA      n/c n/c
Cyclin D1 + + n/c n/c n/c
Cox2 + + n/c n/c n/c
VEGF n/c + n/c   +
p-b-catenin ud n/c n/c ud +
d-catenin +    n/c ud
Lamininb-3 + n/c n/c n/c n/c
E-cadherin n/c + n/c   ud
PSA ud ud   n/c +
 ¼decrease; n/c¼no change; +¼increase; Cox-2¼cyclooxygenase 2;
IGFBP¼IGF binding protein; Mdr¼multi-drug resistance protein; PCNA¼prolifer-
ating cell nuclear antigen; PSA¼prostate specific antigen; SHBG¼sex hormone-
binding globulin; ud¼undetected; VEGF¼vascular endothelial growth factor.
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smediated transfection. Initially, twelve clonal cell lines, MDA ERa
line 1 to MDA ERa line 12, were selected, tested, and found to
express ERa protein (data not shown). We then measured cell
growth in early passage clones in response to 2.5ngml
 1
oestradiol after 24h using growth assays for six of the faster
growing cell lines (data not shown). We also purposely chose to
test several slower growing cell lines. To do this, cells from five
clones were manually counted after 5 and 7 days of 2.5ngml
 1
oestradiol treatment (data not shown). Several clones with
modestly higher growth rates in response to 2.5ngml
 1 oestradiol
compared to the original MDA-wt cell line were identified in these
two initial assays. The ERa line 5 cells (MDA-ERa5) was selected as
a faster growing cell line for further testing. They have a similar
doubling time to the MDA-wt cells. We also chose ERa line 7 cells
(MDA-ERa7) as a slower growing cell line for additional testing.
We felt that the most relevant way to determine if the addition of
ERa is providing a growth advantage for the MDA-ERa clones was
to perform in vivo experiments. Therefore, we injected the MDA-
ERa5, MDA-ERa7, and MDA-wt cells into athymic Rag1 C57BL/6
female mice using oestradiol or placebo pellets in the mice
implanted with the MDA-ERa clones. The MDA-ERa7 cells in mice
with exogenous oestrogen formed heavier tumours (Figure 3A)
compared to the other groups (164 vs 24–81mg) and grew to a
considerably larger size (Figure 3B) compared to any of the other
experimental groups (172 vs 41–103mm
3) (ANOVA Po0.01 with
Newman–Keul’s multiple comparison test Po0.01 or more for all
groups). The MDA-wt grew slowest although this was not
statistically significant compared to any of the other groups except
for the MDA-ERa7 with exogenous oestrogen. The tumours in the
groups inoculated with MDA-ERa5 cells in the presence or absence
of exogenous oestradiol and the MDA-ERa7 cells in the absence of
exogenous oestradiol all grew at almost the same rate.
To confirm this finding we performed a second experiment
implanting just the MDA-wt and MDA-ERa7 cells. We again
utilised the Rag-1 mice but this time the mice were ovariectomised.
In addition, both the mice implanted with MDA-ERa7 cells and
those implanted with MDA-wt cells received either oestradiol or
placebo pellets. As before, the MDA-ERa7 cells implanted into the
mice that received exogenous oestradiol grew much faster as
measured by tumour weight (Figure 3C; 198 vs 68–102mg) and
size (Figure 3D; 399 vs 53–103mm
3) in a manner that was
statistically significant (ANOVA Po0.01 with Newman–Keuls
multiple comparison test Po0.01 or more for all groups). The
MDA-wt cells in the absence of oestradiol pellets grew slightly
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Figure 3 Growth of MDA-wt and clones expressing ERa in response to oestradiol in vivo. Rag1 mice were injected with the cell lines shown along the x
axis in the presence (E) or absence (C) of oestradiol pellets. Mice were intact for experiment 1 and ovariectomised in experiment 2. Tumours were excised,
weighed and measured at the end of the experiment. The average volume in millimetres of the tumours are shown in (A) and (C) and the average weight in
milligrams are shown in (B) and (D) along the y axis for experiments one and two respectively. The. volume for each individual tumour was computed
according to the formula length ((longest dimension)   width squared (widest point at right angle to length) 0.52). The different groups are shown along
the x axis. Bars represent standard error of the mean. An ‘a’ above the bars shows groups that are statically different than all other groups as determined by
ANOVA with Newman–Keul’s multiple comparison post-test (Po0.01).
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sslower than the other cells while the MDA-wt cells in the presence
of oestradiol pellets and the MDA-ERa7 cells in the absence of
oestradiol pellets grew at similar rates. However, none of these
three groups were significantly different from the others as
determined by ANOVA with Newman–Keul’s post test. The
tumour take for the MDA-ERa7 cells was 8 of 10 for exp 1 and 7
of 8 for exp 2 in the presence of exogenous oestradiol. In the
absence of exogenous oestradiol the tumour take for the MDA-
ERa7 cells was 10 of 10 and 11 of 11 for exp 1, and exp 2,
respectively. These results establish that the MDA-ERa7 cell line
readily forms tumours in vivo and is oestrogen responsive in vivo.
In vitro growth and signalling of MDA-ERa7 and MDA-wt
cells in response to Acrp30
In these in vitro studies we increased the level of Acrp30 to a range
of 2.5–20mgml
 1 to obtain more physiological levels and utilised
only the MDA-wt and MDA-ERa7 cell lines to evaluate the
potential interplay of ERa and Acrp30. We also examined the role
of two different forms of Acrp30, full length (Acrp30), and globular
(gAcrp30). The use of gAcrp30 resulted in a reduction in cell
proliferation for the MDA-ERa7 cells (Figure 4A) that was
statistically significant at 2.5–10mgml
 1 of gAcrp30 tested
(ANOVA P¼0.0001, Dunnett’s Po0.05–0.01). There was also a
slight reduction in the growth of the MDA-wt cells after 48 hours
but this was not significant. The difference in growth between the
MDA-ERa7 and MDA-wt cells was statistically significant at
Acrp30 concentrations of 2.5 and 10.0mgml
 1 (Newman–Keuls
Po0.05). The treatments of the two cell lines also differed from
each other as a whole by the Student’s t-test P¼0.0254. We found
only a modest decrease in cell growth by full length Acrp30 after
48h of treatment (Figure 4B). There was a slight downward trend
at the highest level of Acrp30 but it was not statistically significant.
This indicates that the ERþ MDA-ERa7 cells are more responsive
to growth inhibition by gAcrp30 than the ER-MDA-wt cells.
We have investigated some of the possible mechanisms for this
growth reduction by identifying increases or decreases in
phosphorylation of several growth-associated signalling pathway.
We found that gAcrp30 and Acrp30 treatment inhibited the
signalling in MDA-ERa7 and MDA-wt cells associated with
stimulation of resting cells by the growth factors found in FCS.
Figure 5A shows phosphorylation as an indicator of activation for,
JNK1, JNK2, Akt Thr308, Akt Ser473, Stat3, and ERK. In the ERþ
MDA-ERa7 cells, the phosphorylation of JNK2 but not JNK1 is
greatly stimulated by 5% FCS and the increase can be inhibited by
gAcrp30 and to a lesser extent Acrp30 (Figure 5A and 5D).
However, in the ER-MDA-wt cells JNK2 was not stimulated as
much and addition of Acrp30 actually resulted in an increase in
JNK2 phosphorylation. A major difference between the two cell
lines is that FCS stimulation of the MDA-wt cells results in
phosphorylation of the Akt pathway. Both Thr308 and Ser473 are
phosphorylated by the presence of FCS and the levels of
phosphorylation of both are decreased by Acrp30 and to a greater
extent by gAcrp30 (Figure 5A and 5C). The ERþ MDA-ERa7 cells
did not show an increase in Akt phosphorylation in response to
FCS. We also tested two other signalling pathways for activation in
the MDA-wt and MDA-ERa7 cells. We did not find any changes in
the phosphorylation of either ERK or Stat3. Finally, we investigated
the effects of high-dose (20mgml
 1) Acrp30 after 24 hours of
treatment on AdipoR1, AdipoR2 Ob-Rb, Ob-R, and PARP
(Figure 5B). We found that while all of these proteins are
expressed by both the MDA-wt and the MDA-ERa7 cells none of
these proteins were significantly regulated in this experiment. In
addition, we did not see any PARP cleavage under these
conditions.
DISCUSSION
The number of women in the United States who are obese has
doubled in the past 25 years. As the average body mass index
climbs, the overall levels of Acrp30 will decline making this area of
research progressively more important (Smigal et al, 2006; Wyatt
et al, 2006). We have been able to show that five different breast
cancer cell lines express either AdipoR1 and/or AdipoR2 protein.
Previously, mRNA for AdipoR2 and protein for AdipoR1 had been
detected in MCF-7, T47D and MDA-MB-231 cells (Dieudonne et al,
2006; Arditi et al, 2007). We confirmed the protein expression and
found that AdipoR1 protein was also expressed by SK-BR-3 cells.
Our results also indicate AdipoR2 protein was expressed by MCF-7,
T47D, MDA-MB-231, and MDA-MB-361 breast cancer cells.
Additionally, these receptors appear to be functional since in
some breast cancer cell lines growth was inhibited by the addition
of Acrp30 (Figure 1). We did not find large changes in the cell cycle
indicators, PCNA or cyclin D1, possibly due to the use of serum-
free media, which may have caused the cells to enter a G0 state in
which PCNA and cyclin D levels were already relatively low. We
did find that caspase-8 and PARP appeared to be activated by
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Figure 4 Growth of MDA-wt and MDA-ERa7 cells in response to gAcrp30 and Acrp30 in vitro. The MDA-wt (checkered bars) and MDA-ERa7 (filled
bars) cells are shown with cell growth as a percent along the y axis. Cells in only serum-free L-15 were considered to be 100%. The concentrations of
gAcrp30 (A) or Acrp30 (B) are shown along the x axis. The assays were performed in triplicate and repeated a total of three separate times. Bars represent
standard error of the mean of the three different experiments. An ‘a’ corresponds to significantly different from the 0 control of the same cell line as
determined by ANOVA with the Dunnett’s post-test and ‘b’ corresponds to a significant difference between the two cell lines at the same concentration as
determined by ANOVA with the Newman–Keul’s test.
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sAcrp30 in ERþ cell lines (Figure 2). These findings suggest that
apoptosis was initiated in ERþ but not ER  cell lines by Acrp30
in this serum-free experiment.
To better understand why some women would be more
adversely affected by obesity, we initially compared both Her2/
neu status and ERa status in conjunction with the response of the
cell lines we examined for decreased proliferation in response to
Acrp30. Table 5 shows that two of the lines that did not express
Her2/neu, the MCF-7 and T47D, did decrease their proliferation in
response to Acrp30 but that the MDA-MB-231 line which also lacks
Her2/neu did not decrease its proliferation in response to Acrp30.
Of the two lines that expressed Her2/neu, the SK-BR-3 cells did
have a decrease in proliferation but the MDA-MB-361 cells did not.
When we examined the status of ERa in these cell lines as
compared to decreased proliferation in response to Acrp30, we
found that the MCF-7 and T47D cells which express ERa had a
decrease in proliferation but that the MDA-MB-361 cells which
also express ERa did not exhibit the same decrease. Of the cells
that did not express ERa, SK-BR-3 had a decreased proliferation
rate at higher Acrp30 levels as compared to MCF-7 and T47D cells
but the MDA-MB-231 cells did not. Because there appeared to be a
relationship between expression of ERa and decreased sensitivity
of the cells’ antiproliferation response to Acrp30, we chose to
further investigate the interaction of Acrp30 and ERa by
developing a new cell line designated MDA-ERa7. This cell line
expresses ERa and is oestrogen responsive in vivo since it
exhibited increased growth in response to exogenous oestradiol
(Figure 3). Other investigators have transfected ERa into MDA-
MB-231 cells and have found no change in growth (Touitou et al,
1991; Bandyopadhyay et al, 2007) or even a decrease in the
presence of oestradiol (Jiang et al, 1992). The difference may be
attributable to clonal variation or the fact that we first tested the
MDA-ERa7 cells soon after selection. Interestingly, while initial
experiments with very early passage MDA-ERa7 cells suggested it
was oestrogen responsive, in vitro testing with later passages of
MDA-ERa7 cells showed little or no increase in growth in response
to oestradiol (data not shown) despite the fact that similar
passages were responsive to oestradiol in vivo. This may be due to
interactions between oestradiol and other growth factors that
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Figure 5 Alteration of signalling pathways by Acrp30 and gAcrp30. MDA-wt and MDA-ERa7 cells were treated with 10mgml
 1 of gAcrp30 or full-length
Acrp30 for 24h in serum-free media. After pretreatment 5% FCS was added to the cultures indicated for 15min (A)o r2 4h( B). The different antibodies
used are shown along the side and the cell lines with treatments are shown above the lanes. In (C) (MDA-wt) and (D) (MDA-ERa7) densitometry is shown
of (A) that has been normalised to b-actin. The x axis is the different proteins and the y axis is percent where the unstimulated control is set to 100%. Solid
bars are untreated (lanes 1 and 5), diagonal slashes are 5% FCS (lanes 2 and 6), checkered bars are 5% FCS with Acrp30 pretreatment (lanes 3 and 7) and
horizontal bars are 5% FCS with gAcrp30 pretreatment (lanes 4 and 8).
Table 5 ERa and Her2/neu status of breast cancer cell lines and
response to Acrp30
ERa-
positive
Overexpress
Her2/neu
Proliferation in response to
Acrp30
MCF-7 +      
T47-D +     
MDA-MB-
361
++ + N o
SK-BR-3   +++  
MDA-MB-
231
   No
 ¼decrease; +¼increase.
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swould be possible in vivo but that did not occur in our in vitro
system due to the fact that we used serum-free media to perform
our oestradiol growth experiments. These results illustrate that in
vivo growth and in vitro growth can be very different.
When we tested the effects of Acrp30 and gAcrp30 using in vitro
assays we found that MDA-ERa7 cells have decreased cell growth
and were more sensitive to gAcrp30 as compared to the parental
MDA-wt cells (Figure 4A). These decreases in proliferation may be
attributable to decreased signalling through JNK2 since phosphor-
ylation of JNK2 by FCS is inhibited by adiponectin, particularly
gAcrp30 (Figure 5). The concentration levels of the receptors,
AdipoR1 and AdipoR2, did not seem to be involved in cellular
response since they were very similar (Figure 5B). Interestingly,
the ERaþ MDA-ERa7 cells did not show phosphorylation of Akt
following serum stimulation even though the parental MDA-wt
cells did (Figure 5).
We did not find any indication of growth inhibition in
relationship to the cell cycle as no changes in levels of cyclin D1
or PCNA in the absence of serum were detected. However, we did
find that the ERþ cells treated with low doses of Acrp30 appear to
have an increase in apoptosis. This was suggested by the increase
in cleaved caspase-8 and cleaved PARP in these cells. Other reports
have found that apoptosis is involved in growth inhibition by
Acrp30 by the use of TUNEL or annexin V assays (Kang et al, 2005;
Dieudonne et al, 2006; Wang et al, 2006). We have extended those
earlier observations by identifying increased cleavage of caspase-8
and PARP following treatment with Acrp30. We also looked for
cleavage of caspase-3, caspase-6, and caspase-9 but did not find
any changes due to Acrp30 treatment suggesting that under
these conditions the parts of the apoptosis pathway controlled by
these proteins was not being utilised.
Several groups reported previously that MDA-MB-231 cells were
growth inhibited by Acrp30 (Kang et al, 2005; Wang et al, 2007).
However, in our hands proliferation of this cell line was not
statistically inhibited by the addition of Acrp30. This lack of
agreement may be attributable to different culture conditions,
subclone variation of the cells and/or the use of different sources of
Acrp30. We purchased Acrp30 while the other groups made theirs
using at least three different methods.
Our study is one of the first to investigate the function of
gAcrp30 vs Acrp30. Very little work has been done in this area with
only one previous mention that gAcrp30 did not affect MDA-MB-
231 cells growth but the data were not shown (Wang et al, 2006). In
our hands the addition of gAcrp30 to MDA-MB-231 cells resulted
in fewer cells after 48 hours but the reduction was not statistically
significant. Previous work has shown that AdipoR1 has a higher
affinity for gAcrp30 (Yamauchi et al, 2003a). Our study was not
able to address which of the Acrp30 receptors was most important
for the reduction in cell number since our cell lines expressed both
receptors. Additional work using shRNA to knockout AdipoR1,
AdipoR2 or both receptors may help to clarify the roles of the two
receptors with regards to cell growth and/or death.
Here, cell growth inhibition by Acrp30 was examined indepen-
dently of any other serum factors. However, the interplay between
Acrp30 and other growth factors has been shown to be important
for Acrp30’s ability to inhibit cell proliferation (Wang et al, 2005).
With respect to breast cancer, and obesity, leptin has been an
adipokine implicated in mammary tumorigenesis (Hu et al, 2002;
Cleary et al, 2003; Frankenberry et al, 2006; Garofalo et al, 2006).
Overweight or obese individuals usually have elevated levels of the
growth factor leptin, which is positively correlated to body mass
index while Acrp30 is negatively correlated with body mass index.
We and others are now showing that Acrp30 may be an important
negative regulator of breast cancer cell growth (Miyoshi et al, 2003;
Kang et al, 2005; Dieudonne et al, 2006). In particular, we are
trying to assess the interrelationship of these two adipokines on
tumour growth and development. It is likely that a balance
between the two adipokines will determine if a tumour increases or
decreases in size.
Our current study has illustrated that Acrp30 may be involved in
apoptosis as well as inhibition of growth factors found in serum
which initiate proliferation through the JNK and Akt pathways.
This is consistent with a prior study showing that pretreatment of
human aortic smooth muscle cells with Acrp30 inhibited the
function of growth factors in serum (Wang et al, 2005). Previously
it had been anticipated that there would be increased levels of
growth factors released during refeeding following calorie restric-
tion which would enhance tumour development; however, our
previous in vivo findings indicated that intermittent calorie
restriction resulted in increased mammary tumour latency and
decreased tumour incidence (Cleary et al, 2002, 2007). Human
findings on calorie restriction indicate that serum Acrp30 levels
increased following weight loss either through diet (Weiss et al,
2006), MacLean vertical banded gastroplasty or biliopancreatic
diversion with duodenal switch (Kotidis et al, 2006). We are
currently investigating the levels of Acrp30 during calorie
restriction in vivo with ongoing mouse mammary and prostate
tumorigenesis studies. We feel that factors in the serum of the
mice, specifically adipokines have the ability to function as both
growth stimulators such as has been shown for leptin or as growth
inhibitors such as seems to be the case with Acrp30 for breast
cancer. Additional experiments will confirm and define the roles of
adipokines such as Acrp30 and leptin and determine how the
balance of the two impact breast cancer cell growth and death.
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